Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Launched by CELLENKOS, INC. · Jun 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CK0804, which is being tested as an additional therapy for people with myelofibrosis who are not getting enough benefit from their current medication, ruxolitinib. Myelofibrosis is a type of blood cancer that affects the bone marrow, and this study aims to see if CK0804 can help improve patients' health and manage their symptoms better. The trial is currently looking for participants aged 18 and older who have been on ruxolitinib for at least three months but are still experiencing symptoms or issues related to their condition.

Participants in the trial will receive CK0804 and will be closely monitored for safety and how well they tolerate the treatment. To be eligible, participants must have a life expectancy of more than six months and must have specific health conditions related to myelofibrosis. It’s important for potential participants to understand the requirements, including avoiding pregnancy during the study. Overall, this trial hopes to find a better treatment option for those who are not receiving adequate relief from their current medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study.
• • 2. Age above 18 years inclusive at the time of signing the ICF.
• • 3. Participants who fulfill the diagnostic criteria of myelofibrosis including primary myelofibrosis and myelofibrosis arising from polycythemia vera and essential thrombocythemia
• • 4. Life expectancy is greater than 6 months.
• • 5. Subject has been receiving ruxolitinib therapy, is unlikely to benefit from further ruxolitinib monotherapy in the opinion of the investigator; AND meeting the following criteria: receiving ruxolitinib \>3 months prior to enrollment; AND stable dose for 8 weeks before starting therapy with CK0804
• 6. Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of:
• • presence of grade ≥2 anemia or thrombocytopenia or neutropenia, OR
• • presence of disease-related symptoms, as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN SAF TSS) score of ≥10 points, OR
• • documented splenomegaly of at least 5 cm below the costal margin as measured by physical examination or splenomegaly as documented by ultrasound or MRI.
• • 7. Willingness to avoid pregnancy or fathering children based on the criteria below
• • Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last study treatment dose and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing should be communicated to the participants and their understanding confirmed.
• • Women of childbearing potential must have a negative serum pregnancy test at screening before the first dose (within 3 days of the first study treatment dose) and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through the safety follow-up visit and must not donate oocytes during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed,
• • Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible.
• • 8. ECOG performance status of 0 to 2
• Exclusion Criteria:
• • 1. Any major surgery within 28 days before the first dose of study treatment.
• • 2. Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation.
• • 3. Received chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent to treat the participant's disease, with the exception of ruxolitinib, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
• • 4. Participant has received splenic irradiation within the past 6 months.
• • 5. Significant concurrent, uncontrolled medical condition or infections, which in the opinion of the principal investigator may interfere in the study participation.
• • 6. Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
• • 7. Women who are pregnant or breastfeeding.
• • 8. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
• • 9. Participants with laboratory values at screening as defined
• • Platelets \< 50 × 10\^9/L without the assistance of growth factors, thrombopoietic factors, or platelet transfusions
• • ANC \< 0.5 × 10\^9/L
• • ALT ≥ 2.5 × ULN
• • AST ≥ 2.5 × ULN
• • Direct Bilirubin \> 2.0 × ULN
• • ALP ≥ 3 × ULN
• • Creatinine clearance \< 50 mL/min according to Cockcroft-Gault formula.
• • 10. Unwillingness to be transfused with blood components including RBC and platelet transfusions.
• • 11. Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend the ICF or unwillingness to sign the ICF.